Myriad rises on new 4-year contract, pricing terms with UnitedHealthcare

Myriad Genetics

11/10/2023 15:41

** Shares of genetic testing company Myriad Genetics
 MYGN.O  rise ~1.6% to $15.56 
    ** Co says it agreed on a new long-term agreement with
UnitedHealthcare, a unit of UnitedHealth Group  UNH.N 
    ** The agreement includes pricing for MYGN's products,
including MyChoice CDx and Prolaris - co  
    ** Revised contract is effective Jan. 1, 2024 and runs
through Dec. 31, 2027
    ** Including session moves, shares up ~8.8% YTD


 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))